“…Methylimidazolium β-cyclodextrin derivatives 6 I,II,III,IV,V,VI,VII -heptadeoxy-6 I,II,III,IV,V,VI,VII -heptakis[4-((2,2-dimethyl-3-(1-methyl-1 H -imidazol-3-ium-3-yl)propoxy)methyl)-1 H -1,2,3-triazol-1-yl]-2 I - O -[2-(3-(6-((1,3-dioxo-2-propyl-2,3-dihydro-1 H -benzo[ de ]isoquinolin-6-yl)amino)hexyl)thioureido)ethane-1-yl]-cyclomaltoheptaose hepta(hydrogen carbonate) and 6 I,II,III,IV,V,VI,VII -heptadeoxy-6 I,II,III,IV,V,VI,VII -heptakis[4-((2-methyl-3-(1-methyl-1 H -imidazol-3-ium-3-yl)-2-((1-methyl-1 H -imidazol-3-ium-3-yl)methyl)propoxy)methyl)-1 H -1,2,3-triazol-1-yl]-cyclomaltoheptaose tetradeca(hydrogen carbonate) (MIM7NBCD-X and MIM14BCD-X; Figure ) were prepared by published procedures (ref , compounds 95 and 91 ). Bicarbonate counterions were subsequently replaced with selected counterions by adding stoichiometric amounts of matching acid aqueous solution to 2–5% solution of the corresponding bicarbonate in methanol or water; evaporation under reduced pressure followed.…”